Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
While incretins are of great interest for the therapy of diabetes 2, the focus has recently been brought to the thyroid, since rodents treated with glucagon-like peptide-1 (GLP-1) analogs were found to occasionally develop medullary thyroid carcinomas. Incretin receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) were therefore measured in various rodent and human thyroid conditions. In vitroGLP-1 and GIP receptor autoradiography were performed in normal thyroids, C-cell hyperplasia and medullary thyroid carcinomas in rodents. Receptor incidence and density were assessed and compared with the receptor expression in human thyroids, medullary thyroid carcinomas, and TT cells. GLP-1 receptors are expressed in C cells of normal rat and mice thyroids. Their density is markedly increased in rat C-cell hyperplasia and medullary thyroid carcinomas, where their incidence amounts to 100%. GIP receptors are neither detected in normal rodent thyroids nor in C-cell hyperplasia, but are present in all rat medullary thyroid carcinomas. No GLP-1 or GIP receptors are detected in normal human thyroids. Whereas only 27% of all human medullary thyroid carcinomas express GLP-1 receptors, up to 89% express GIP receptors in a high density. TT cells lack GLP-1 receptors but express GIP receptors. GLP-1 receptors are frequently expressed in non-neoplastic and neoplastic C cells in rodents while they are rarely detected in human C-cell neoplasia, suggesting species differences. Conversely, GIP receptors appear to be massively overexpressed in neoplastic C cells in both species. The presence of incretin receptors in thyroid C cell lesions suggests that this organ should be monitored before and during incretin-based therapy of diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Healthy human thyroid C cells do not express GLP 1 receptors”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [56]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“During preclinical development, it was observed in animal studies evaluating the long-term effect of GLP-1 analogs that a significant number of animals developed medullary thyroid carcinomas [”
BackgroundGerm-line mutations in p27 Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans
Pellegata, N. S., Quintanilla-Martinez, L., Siggelkow, H., Samson, E., Bink, K., Höfler, H., Fend, F., Graw, J., & Atkinson, M. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603877103 · Cited by 644
Self-citationThe incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“This observation is puzzling. In a study on GLP-1 receptors in cancer tissue [”
Self-citationIslet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan
Wang, L.-Y., Hatch, M., Chen, C.-J., Levin, B., You, S.-L., Lu, S.-N., Wu, M.-H., Wu, W.-P., Wang, L.-W., Wang, Q., et al. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960904)67:5<620::aid-ijc5>3.0.co;2-w · Cited by 259
Self-citationEhses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H.-U., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159
Kim, S.-J., Nian, C., Widenmaier, S., & McIntosh, C. H. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00325-07 · Cited by 136
Research works printed but not linked: 1
- 10.1002%2F%28SICI%291097-0215%2819960904%2967%3A5%3C644%3A%3AAID-IJC9%3E3.0.CO%3B2-U · doi:10.1002/(sici)1097-0215(19960904)67:5<644::aid-ijc9>3.0.co;2-u
Cited by
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161
On-target and Off-target-based Toxicologic Effects
Rudmann, D. G. (2012) · Toxicologic Pathology · doi:10.1177/0192623312464311 · Cited by 176
Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., & Milicevic, Z. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 149
Liraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145
“Another recent study using an evenmore specific method to detect (and rule out) GLP-1 receptors in tissues (a radioligand assay) did not confirmGLP-1 receptors in human thyroid tissue outside C cells (35).”
ResultIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“A very sensitive radioligand assay involving GLP-1R autoradiography was performed to analyse GLP-1R expression in rodent versus human thyroid [183].”
MethodGlucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Self-citationMorgat, C., Mishra, A. K., Varshney, R., Michèle Allard, A., Fernandez, P., & Hindié, E. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.142000 · Cited by 103
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment
Hariyanto, T. I., & Kurniawan, A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100336 · Cited by 100
Bailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 84
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
“Moreover, GLP-1 receptors are also expressed at high levels in various tumors, such as pheochromocytoma, medullary thyroid carcinoma, meningioma, embryonic tumors, and prostate carcinomas.(2,4,5) Interestingly, in vitro studies and animal models showed that GLP-1 receptor activation could promote or inhibit tumor grow…”
BackgroundGLP1 and cancer: friend or foe?
Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0111 · Cited by 73
Diabetes mellitus and thyroid diseases
Nishi, M. (2018) · Diabetology International · doi:10.1007/s13340-018-0352-4 · Cited by 89
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
Körner, M., Christ, E., Wild, D., & Reubi, J. C. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00158 · Cited by 73
Self-citationClinical Impact of Liraglutide as a Treatment of Obesity
Alruwaili, H., Dehestani, B., & le Roux, C. W. (2021) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s276085 · Cited by 93
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Li, R., Xu, W., Luo, S., Xu, H., Tong, G., Zeng, L., Zhu, D., & Weng, J. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0792-2 · Cited by 59
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Mannucci, E., Mosenzon, O., & Avogaro, A. (2016) · Diabetes Care · doi:10.2337/dcs15-3024 · Cited by 48
Reubi, J. C., & Maëcke, H. R. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186882 · Cited by 51
Self-citationJung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Old and New Peptide Receptor Targets in Cancer: Future Directions
Reubi, J. C. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-27994-2_34 · Cited by 30
Self-citationEffect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man
Boess, F., Bertinetti-Lapatki, C., Zoffmann, S., George, C., Pfister, T., Roth, A., Lee, S. M. L., Thasler, W. E., Singer, T., & Suter, L. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0186 · Cited by 29
Incretin Therapy – Present and Future
Garber, A. J. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.307 · Cited by 31
Regazzo, D., Barbot, M., Scaroni, C. M., Albiger, N. M. E., & Occhi, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09536-6 · Cited by 33
Thyroid safety in patients treated with liraglutide
Gallo, M. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346749 · Cited by 27
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
Radionuclides for Imaging and Therapy in Oncology
Velikyan, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00017-7 · Cited by 30
Song, Y., Zhou, M., Cao, Y., Qi, J., Geng, J., & Liu, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5752 · Cited by 23
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
GIPR expression in gastric and duodenal neuroendocrine tumors
Sherman, S. K., Maxwell, J. E., Carr, J. C., Wang, D., O'Dorisio, M. S., O’Dorisio, T. M., & Howe, J. R. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.01.044 · Cited by 22
Gigoux, V., & Fourmy, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00050 · Cited by 22
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings
Regazzo, D., Bertazza, L., Galletta, E., Barollo, S., Mondin, A., Zovato, S., Iacobone, M., Zilio, E., Scaroni, C., Radu, C. M., et al. (2022) · Endocrine-Related Cancer · doi:10.1530/erc-21-0258 · Cited by 17
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors
Lacroix, A., Bourdeau, I., Chasseloup, F., Kamenický, P., Lopez, A.-G., Louiset, E., & Lefèbvre, H. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00200-6 · Cited by 19
Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer
Kushchayeva, Y. S., Kushchayev, S. V., Jensen, K. E., & Brown, R. J. (2022) · Cancers · doi:10.3390/cancers14030555 · Cited by 20
Chehade, J. M., Alcalde, R., Naem, E., Mooradian, A. D., Wong, N. C. W., & Haas, M. J. (2012) · Metabolism · doi:10.1016/j.metabol.2012.07.005 · Cited by 15
Cao, Y., & Liu, X.-M. (2014) · Endocrine · doi:10.1007/s12020-014-0354-3 · Cited by 14
Abdul-Maksoud, R. S., Elsayed, W. S. H., Rashad, N. M., Elsayed, R. S., Elshorbagy, S., & Hamed, M. G. (2022) · Gene · doi:10.1016/j.gene.2022.146597 · Cited by 13
Incretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Ji, L., He, X., Min, X., Yang, H., Wu, W., Xu, H., Chen, J., & Mei, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465881 · Cited by 12
Therapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 13
Reubi, J. C., Fourmy, D., Cordomí, A., Tikhonova, I. G., & Gigoux, V. (2019) · Peptides · doi:10.1016/j.peptides.2019.170229 · Cited by 10
Self-citationCurrent Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 7
Impaired glucose metabolism treatment and carcinogenesis
Matyszewski, A., Czarnecka, A. M., Kawecki, M., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3324 · Cited by 7
Kannan, S., & Nasr, C. E. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13066 · Cited by 8
Paradoxical GH increase after oral glucose load in subjects with and without acromegaly
Ceccato, F., Vedolin, C. K., Voltan, G., Antonelli, G., Barbot, M., Basso, D., Regazzo, D., Scaroni, C. M., & Occhi, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02138-9 · Cited by 6
Nogare, M. D., D’Annunzio, S., Vazza, G., Regazzo, D., Picello, L., Denaro, L., Voltan, G., Scaroni, C. M., Ceccato, F., & Occhi, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119264 · Cited by 6
Activation of G-Protein-Coupled Receptors and Thyroid Malignant Tumors: The Jury is Still Out
Gagel, R. F. (2011) · Endocrine Practice · doi:10.4158/ep.17.6.957 · Cited by 5
Sánchez, Y. A., García, F. A., del Sol, D. O., Valdés‐Tresanco, M. E., Ortiz, C. D., Ramírez, B. S., & Alonso, I. P. (2023) · Physical Sciences Reviews · doi:10.1515/psr-2022-0288 · Cited by 4
Cytology and Pathology: Pitfalls and Challenges
Asa, S. L., & Mete, Ö. (2016) · Springer eBooks · doi:10.1007/978-3-319-39412-1_4 · Cited by 3
Haase, A., Alefeld, E., Yalinci, F., Meenen, D. V., Busch, M. A., & Dünker, N. (2024) · Cancers · doi:10.3390/cancers16091656 · Cited by 2
The effects of incretins as a double-edged sword on cancer
Mavaddat, H., Fouladi, A., Peyrovinasab, A., Khayatan, I., Targhi, H. J., Fakhri, M., Andarzbakhsh, K., Büsselberg, D., Razavi, S. M., & Rezazadeh, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11062-5 · Cited by 2
Exenatide Once Weekly: Opportunities in the Primary Care Setting
Davidson, J., Nikkei, C., & Grimm, M. (2013) · Postgraduate medicine · doi:10.3810/pgm.2013.05.2662 · Cited by 4
Aty, O. A. A.-E., & El-Din, S. B. (2015) · Basic Sciences of Medicine · Cited by 2
GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity
Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 2
Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide
Koro, C. E., Pientka, J., Bainbridge, V., O’Donnell, N., Stender, M., & Stemhagen, A. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0128-3 · Cited by 2
Thyroid Neuroendocrine Neoplasms
Asa, S. L., & Mete, Ö. (2020) · Springer eBooks · doi:10.1007/978-3-030-54391-4_7 · Cited by 2
Radionuclides for imaging and therapy in oncology
Velikyan, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22253-5.00026-1 · Cited by 1
Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
Renehan, A. G., & Pollak, M. (2026) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-26-0018 · Cited by 2
Dipeptidil peptidasa IV y su implicación en el cáncer
Sánchez, Y. A., Gómez, H., Valiente, P. A., Chávez, M. D. L. A., & Pascual, I. (2014) · Biotecnología aplicada · Cited by 3
Giri, B., Sarkar, M., & Dey, S. (2017) · Journal of Stem Cell and Regenerative Biology · doi:10.15436/2471-0598.16.017 · Cited by 1
Glucagonlike Peptide-1 Receptor Expression in the Thyroid Gland: A Case of “Hide-and-Seek”?
Sternthal, E. (2011) · Endocrine Practice · doi:10.4158/ep.17.6.955 · Cited by 1
Effect of Obestatin on Bone Turnover in Normal and Obese Male Albino Rats
KHALIL, M. D. R. H. I. S. S. (2019) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2019.52355
Medikamentöse Adipositastherapie bei Typ-2-Diabetes
Kantowski, T., Wiesch, C. S. Z., Aberle, J., & Lautenbach, A. (2024) · CME · doi:10.1007/s11298-024-3862-3
Jaradat, J. H., Alahmad, R., Jaghbeer, M. A., Abdelaziz, A. A., Afifeh, N. A., Afifeh, G. A., Rao, A., Alzoubi, A., & Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.96071 · Cited by 3
Chasseloup, F. (2022) · theses.fr (ABES) · doi:10.70675/ddec5b6dzf376z4aadz9970zf0bf052c6f02
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644 · Cited by 1
Li, Y., Zeng, H., Du, F., Wu, L., Ke, X., Li, P., Song, Y., Zhao, H., & Wang, S. (2026) · International Journal of Cancer · doi:10.1002/ijc.70642
Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
Rajan, L., Hofland, J., Mulugeta, E., & de Herder, W. W. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag135
Jin, C. A., Many, G. M., Spurrier, C. S. R., Borsellino, P., Wheeler, M. T., Adkins, J., Snyder, M. P., Newgard, C. B., Radom‐Aizik, S., Cooper, D. M., et al. (2026) · Physiological Genomics · doi:10.1152/physiolgenomics.00171.2026
Zhong, Q., Smith-Lopez, K., & Diamond, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.01000-9
Metadata
- Authors
- Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C.
- Affiliations
- University of Bern (CH)
- Helmholtz Munich (DE)
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 94
- Issue
- 4
- Pages
- 291-301
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2078709678
- Cited by
- 80
- References
- 20
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 9 · 2013: 9 · 2012: 7
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- incretin receptors, GLP-1 receptor, GIP receptor, medullary thyroid carcinoma, C cells, C-cell hyperplasia, TT cells, type 2 diabetes treatment, species differences, receptor density, thyroid function monitoring
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Humans, Mice, Inbred BALB C, Mice, Inbred C57BL, Receptors, Gastrointestinal Hormone, Thyroid Gland, Thyroid Neoplasms, Tumor Cells, Cultured, Rats, Sprague-Dawley, Rats, Wistar, Receptors, Glucagon, Carcinoma, Neuroendocrine, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.